Alpha Centric Advisors LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Alpha Centric Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$10.44 - $16.48 $287,100 - $453,200	27,500 Added 33.33%	110,000 $1.55 Million
Q1 2023 May 12, 2023	BUY	$10.7 - $15.79 $401,250 - $592,125	37,500 Added 83.33%	82,500 $887,000
Q4 2022 Feb 07, 2023	BUY	$11.42 - $17.05 $22,840 - $34,100	2,000 Added 4.65%	45,000 $674,000
Q3 2022 Nov 08, 2022	BUY	$9.76 - $13.41 $419,680 - $576,630	43,000 New	43,000 $552,000
Q3 2021 Mar 09, 2022	SELL	$11.39 - $16.23 $370,175 - $527,475	-32,500 Closed	0 $0
Q2 2021 Mar 09, 2022	BUY	$13.22 - $19.09 $178,470 - $257,715	13,500 Added 71.05%	32,500 $453,000
Q1 2021 Mar 09, 2022	BUY	$16.68 - $23.97 $58,380 - $83,895	3,500 Added 22.58%	19,000 $352,000
Q4 2020 Mar 11, 2022	BUY	$14.8 - $21.15 $170,200 - $243,224	11,500 Added 287.5%	15,500 $274,000
Q3 2020 Mar 11, 2022	BUY	$15.21 - $25.53 $60,840 - $102,120	4,000 New	4,000 $61,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.